Genome‐wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non‐G‐CIMP glioblastomas with unmethylated MGMT promoter: MGMT‐dependent roles of GPR81. This evidence concerns the gene HCAR1 and glioblastoma.